Home  /  Resource Library  /  Polatuzumab vedotin in combination with venetoclax and rituximab for patients with R/R DLBCL

Polatuzumab vedotin in combination with venetoclax and rituximab for patients with R/R DLBCL

Results of a study investigating polatuzumab vedotin in combination with venetoclax and rituximab for patients with relapsed DLBCL